GlassScriptPhysician profile
Edmund Grant
NPI 1992724736
$19,449.92
in general payments reported to CMS, 2019-2025
70 companies · $2,010 in 2025
The $2,010 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,745 · 2020: $2,058 · 2021: $3,653 · 2022: $3,217 · 2023: $2,973 · 2024: $2,794 · 2025: $2,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,769 · Education: $8.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,768.53 |
| Education | $8.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,823.65 | 2019-2025 | |
| Abbvie INC. | $1,483.13 | 2019-2025 | |
| Amgen INC. | $1,327.41 | 2019-2025 | Uplizna, Aimovig |
| Ucb, INC. | $1,038.73 | 2019-2025 | Rystiggo, Briviact, Zilbrysq |
| Pfizer INC. | $829.05 | 2019-2025 | |
| Biogen, INC. | $802.85 | 2019-2023 | Vumerity |
| Argenx US, INC. | $788.06 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Neurocrine Biosciences, INC. | $682.30 | 2019-2025 | Ingrezza, Ongentys |
| Genzyme Corporation | $653.21 | 2019-2025 | |
| Celgene Corporation | $638.53 | 2021-2025 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $563.12 | 2021-2025 | Hyqvia, Gammagard |
| Acadia Pharmaceuticals INC | $524.66 | 2021-2025 | Nuplazid |
| Lilly USA, LLC | $512.14 | 2019-2025 | Emgality, Amyvid, Reyvow |
| Adamas Pharmaceuticals, INC. | $509.07 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $491.04 | 2019-2025 | Ajovy, Austedo, Austedo Xr |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edmund Grant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.